Osteoporosis in 10 Years Time: a Glimpse into the Future of Osteoporosis

Overview

Journal Ther Adv Musculoskelet Dis

Date 2022 Mar 28

PMID 35342458

Authors

Giovanni Adami

Angelo Fassio

Davide Gatti

Ombretta Viapiana

Camilla Benini

Maria I Danila

Kenneth G Saag

Maurizio Rossini

Affiliations

Soon will be listed here.

Abstract

Patients living with osteoporosis are projected to increase dramatically in the next decade. Alongside the forecasted increased societal and economic burden, we will live a crisis of fractures. However, we will have novel pharmacological treatment to face this crisis and, more importantly, new optimized treatment strategies. Fracture liaison services will be probably implemented on a large scale worldwide, helping to prevent additional fractures in high-risk patients. In the next decade, novel advances in the diagnostic tools will be largely available. Moreover, new and more precise fracture risk assessment tools will change our ability to detect patients at high risk of fractures. Finally, big data and artificial intelligence will help us to move forward into the world of precision medicine. In the present review, we will discuss the future epidemiology and costs of osteoporosis, the advances in early and accurate diagnosis of osteoporosis, with a special focus on biomarkers and imaging tools. Then we will examine new and refined fracture risk assessment tools, the role of fracture liaison services, and a future perspective on osteoporosis treatment.

Citing Articles

Proposed practice parameters for the performance of radiofrequency echographic multispectrometry (REMS) evaluations.

Zambito K, Kushchayeva Y, Bush A, Pisani P, Kushchayeva S, Peters M Bone Jt Open. 2025; 6(3):291-297.

PMID: 40049216 PMC: 11884906. DOI: 10.1302/2633-1462.63.BJO-2024-0107.R1.

Effect of vertebral kyphoplasty versus vertebroplasty on pain and indicators of imaging parameters of the injured vertebrae in patients with osteoporotic vertebral compression fractures: a meta-analysis.

You Z, Wu K, Jiang Y, Chen J J Orthop Surg Res. 2025; 20(1):199.

PMID: 40001072 PMC: 11863920. DOI: 10.1186/s13018-025-05621-6.

Association between air pollution and osteoporosis: A Mendelian randomization study.

Ju M, Liu F, Deng T, Jia X, Xu W, Zhang F Medicine (Baltimore). 2025; 104(8):e41490.

PMID: 39993078 PMC: 11856944. DOI: 10.1097/MD.0000000000041490.

Are Dietary Patterns Relevant for Reducing the Risk of Fractures and Sarcopenia?.

Welch A, Scott J, Cameron D, Yates M Curr Osteoporos Rep. 2025; 23(1):7.

PMID: 39847227 PMC: 11759455. DOI: 10.1007/s11914-024-00899-7.

Associations of Serum Homocysteine with Bone Mineral Density and Osteoporosis Incidence in Chinese Middle-Aged and Older Adults: A Retrospective Cohort Study.

Zou J, Shu M, Chen J, Wusiman M, Ye J, Yang S Nutrients. 2025; 17(1.

PMID: 39796626 PMC: 11723229. DOI: 10.3390/nu17010192.

References

Samelson E, Broe K, Xu H, Yang L, Boyd S, Biver E . Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. Lancet Diabetes Endocrinol. 2018; 7(1):34-43. PMC: 6354581. DOI: 10.1016/S2213-8587(18)30308-5. View

Benny Lam S, Wald M, Rajapakse C, Liu Y, Saha P, Wehrli F . Performance of the MRI-based virtual bone biopsy in the distal radius: serial reproducibility and reliability of structural and mechanical parameters in women representative of osteoporosis study populations. Bone. 2011; 49(4):895-903. PMC: 3167016. DOI: 10.1016/j.bone.2011.07.010. View

Lamy O, Fernandez-Fernandez E, Monjo-Henry I, Stoll D, Aubry-Rozier B, Benavent-Nunez D . Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports. Osteoporos Int. 2019; 30(5):1111-1115. DOI: 10.1007/s00198-018-04820-8. View

Adami G, Saag K, Mudano A, Rahn E, Wright N, Outman R . Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment. Osteoporos Int. 2020; 31(7):1283-1290. PMC: 7365553. DOI: 10.1007/s00198-020-05312-4. View

Recker R, Benson C, Matsumoto T, Bolognese M, Robins D, Alam J . A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2014; 30(2):216-24. DOI: 10.1002/jbmr.2351. View

Papadakis G, Karantanas A, Tsiknakis M, Tsatsakis A, Spandidos D, Marias K . Deep learning opens new horizons in personalized medicine. Biomed Rep. 2019; 10(4):215-217. PMC: 6439426. DOI: 10.3892/br.2019.1199. View

Johnell O, Kanis J . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-33. DOI: 10.1007/s00198-006-0172-4. View

Tsourdi E, Makras P, Rachner T, Polyzos S, Rauner M, Mandanas S . Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. Bone. 2018; 120:44-49. DOI: 10.1016/j.bone.2018.10.001. View

Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S . The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab. 2011; 96(5):1555-9. DOI: 10.1210/jc.2010-2552. View

10.

Martineau P, Leslie W, Johansson H, Oden A, McCloskey E, Hans D . Clinical Utility of Using Lumbar Spine Trabecular Bone Score to Adjust Fracture Probability: The Manitoba BMD Cohort. J Bone Miner Res. 2017; 32(7):1568-1574. DOI: 10.1002/jbmr.3124. View

11.

Khashayar P, Taheri E, Adib G, Zakraoui L, Larijani B . Osteoporosis strategic plan for the Middle East and North Africa region. Arch Osteoporos. 2019; 14(1):20. DOI: 10.1007/s11657-019-0567-4. View

12.

Bonds D, Larson J, Schwartz A, Strotmeyer E, Robbins J, Rodriguez B . Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab. 2006; 91(9):3404-10. DOI: 10.1210/jc.2006-0614. View

13.

Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen E, Guanabens N . Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017; 105:11-17. DOI: 10.1016/j.bone.2017.08.003. View

14.

Cummings S, Ferrari S, Eastell R, Gilchrist N, Jensen J, McClung M . Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2017; 33(2):190-198. DOI: 10.1002/jbmr.3337. View

15.

Bone H, Cosman F, Miller P, Williams G, Hattersley G, Hu M . ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018; 103(8):2949-2957. PMC: 6097601. DOI: 10.1210/jc.2018-00163. View

16.

Bone H, Bolognese M, Yuen C, Kendler D, Miller P, Yang Y . Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011; 96(4):972-80. DOI: 10.1210/jc.2010-1502. View

17.

Stroncek J, Shaul J, Favell D, Hill R, Huber B, Howe J . In vitro injection of osteoporotic cadaveric femurs with a triphasic calcium-based implant confers immediate biomechanical integrity. J Orthop Res. 2019; 37(4):908-915. PMC: 6593990. DOI: 10.1002/jor.24239. View

18.

Shaul J, Hill R, Bouxsein M, Burr D, Tilton A, Howe J . AGN1 implant material to treat bone loss: Resorbable implant forms normal bone with and without alendronate in a canine critical size humeral defect model. Bone. 2021; 154:116246. DOI: 10.1016/j.bone.2021.116246. View

19.

Yang Y, Yujiao W, Fang W, Linhui Y, Ziqi G, Zhichen W . The roles of miRNA, lncRNA and circRNA in the development of osteoporosis. Biol Res. 2020; 53(1):40. PMC: 7493179. DOI: 10.1186/s40659-020-00309-z. View

20.

Adami G, Gatti D, Rossini M, Orsolini G, Pollastri F, Bertoldo E . Risk of fragility fractures in obesity and diabetes: a retrospective analysis on a nation-wide cohort. Osteoporos Int. 2020; 31(11):2113-2122. DOI: 10.1007/s00198-020-05519-5. View